Regeneron Pharmaceuticals (REGN) Advances +28% in 30 Days Following Earnings Beat
Key Takeaways
- Regeneron Pharmaceuticals (REGN) has climbed roughly 28% over the last 30 days, rising from about $651 to approximately $834 per share.
- The move was driven primarily by a strong second-quarter 2026 earnings report, released on July 30, that beat analyst expectations on both revenue and earnings.
- Record quarterly sales from Dupixent, EYLEA HD, and Libtayo, along with the full repayment of the Sanofi development balance, powered investor optimism.
- Over the last quarter, the stock has gained approximately 30%, with nearly all of that advance concentrated in the weeks following the earnings release.
- Near-term catalysts include a November FDA decision on cemdisiran and multiple late-stage pipeline readouts expected later in 2026.
Company Overview and Market Position
Regeneron Pharmaceuticals is a Tarrytown, New York-based biotechnology company focused on discovering, developing, and commercializing treatments for serious diseases. It stands out for its immunology and ophthalmology franchises in particular. Dupixent, developed with Sanofi (SNY), ranks among the top therapies for atopic dermatitis, asthma, and other inflammatory conditions. EYLEA and the higher-dose EYLEA HD, co-developed with Bayer (BAYRY), form the core of its eye-disease portfolio, while Libtayo supports the oncology efforts.
The company’s strength comes from its antibody-discovery platforms and a pipeline of around 50 programs across immunology, oncology, ophthalmology, and genetic medicines. With more than $15 billion in net cash, it holds solid financial flexibility. I often follow the stock because of its diversified revenue streams, recurring pipeline updates, and established partnerships.
Stock Price Performance Over the Last 30 Days and Quarter
REGN shares rose roughly 28% in the past 30 days, moving from a closing price near $651 to about $834 and setting a new 52-week high above the previous peak of $821.11. I checked sector comparisons using Tickeron’s AI Screener to see how this performance stacked up against peers.
Over the full quarter the gain came in around 30%, starting from roughly $639 near the end of May. The stock stayed mostly range-bound from May through much of July before the sharp move after earnings. Most of the quarterly advance occurred in the final three weeks.
Key Drivers Behind the 30-Day Rally
The main catalyst was the second-quarter 2026 results released on July 30. Revenue reached $4.29 billion, up 17% year over year and above the $3.82 billion consensus, while non-GAAP diluted EPS of $14.29 comfortably beat the $10.16 estimate.
Dupixent posted $6.0 billion in global net sales, up 38% on a constant-currency basis. EYLEA HD U.S. sales jumped 52% to $596 million and surpassed legacy EYLEA for the first time, accounting for about 60% of the U.S. franchise. Libtayo sales rose 29% to $489 million, and Sanofi collaboration revenue hit a record $2.2 billion, up 51%. The full repayment of the Sanofi development balance should boost collaboration revenue starting in the third quarter, which management and analysts highlighted as supportive for the second half.
Drivers of Performance Across the Full Quarter
The quarterly trend reflects a shift in the product mix. Legacy EYLEA sales fell 45% year over year amid competition from Roche’s (RHHBY) Vabysmo and biosimilar pressure. At the same time, EYLEA HD and Dupixent continued to expand. Earlier label approvals for Dupixent in chronic spontaneous urticaria and extended EYLEA HD dosing intervals helped reposition investor focus toward the growth areas.
Upcoming Catalysts and What to Watch
Several events could influence the stock ahead. An FDA decision on cemdisiran for generalized myasthenia gravis is expected in November 2026, along with a decision on garetosmab for fibrodysplasia ossificans progressiva. Fourth-quarter readouts from complement programs in paroxysmal nocturnal hemoglobinuria and geographic atrophy, plus Phase III starts in obesity, are also on the calendar.
Commercially, the durability of Dupixent and EYLEA HD growth, the timing of the EYLEA HD pre-filled syringe approval, and the pace of legacy EYLEA decline will matter. The Sanofi collaboration and capital allocation, including share repurchases and the $0.94 quarterly dividend, remain areas of attention. I also reviewed momentum signals with Tickeron’s AI Trend Prediction Engine to better understand potential near-term direction.
Exploring AI-Powered Trading Approaches
In my own research I frequently review Tickeron’s AI Trading Bots to see how automated strategies are currently performing across various tickers. The platform offers hundreds of bots with different timeframes and approaches, and the Trending AI Robots section highlights the top-performing ones that are drawing attention right now. This gives a useful data-driven layer that complements traditional fundamental work.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
Aroon Indicator for REGN shows an upward move is likely
REGN's Aroon Indicator triggered a bullish signal on August 21, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 247 similar instances where the Aroon Indicator showed a similar pattern. In of the 247 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on July 27, 2026. You may want to consider a long position or call options on REGN as a result. In of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for REGN just turned positive on July 28, 2026. Looking at past instances where REGN's MACD turned positive, the stock continued to rise in of 49 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where REGN advanced for three days, in of 310 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 16 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 17 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
REGN broke above its upper Bollinger Band on August 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.708) is normal, around the industry mean (20.145). P/E Ratio (20.639) is within average values for comparable stocks, (22.992). Projected Growth (PEG Ratio) (1.377) is also within normal values, averaging (3.861). Dividend Yield (0.004) settles around the average of (0.018) among similar stocks. P/S Ratio (5.747) is also within normal values, averaging (444.692).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. REGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. REGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock better than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of medicines for the treatment of serious medical conditions
Industry Biotechnology
Advertisement